Market Overview

Gilead Crushes On Earnings, Quickly Gives Up Gains

Share:
Related GILD
Gilead Gets European CHMP's Positive Opinion On Its Type II Variation Application For Truvada
Here Are The 14 Stocks Morgan Stanley Wants You To Focus On During Q2 Earnings
5 Big Drugmakers Reporting Earnings Next Week (Investor's Business Daily)

Shares of Gilead Sciences (NASDAQ: GILD) traded up sharply before turning back, remaining up 1.18 percent to $72.86 in Tuesday's post market session after blowing away analysts' first quarter estimates.

The company reported earnings per share of $1.48 versus the $0.92 estimate. Revenue came in at $5 billion, almost a 100 percent increase year over year.

U.S. product sales for the first quarter rose to $3.63 billion, up over 259 percent compared to the same quarter in 2013 where the company reported a figure of $1.4 billion.

In Europe, product sales increased to $1.02 billion, up over 22 percent from 2013.

For individual product sales, Gilead reported Sovaldi sales at $2.27 billion, crushing estimates of $1.13 billion, while Atripla sales came in at $779.6 million, missing expectations of $888.6 million.

Truvada also missed expectations, with sales coming in at $759.7 million versus the expected $765.6 million.

Non-GAAP research and development (R&D) expenses increased due to the progression of Gilead's clinical studies, particularly in oncology and HIV.

Gilead reiterated full year 2014 guidance.

Posted-In: Earnings News

 

Related Articles (GILD)

View Comments and Join the Discussion!